XtalPi Inc. and CK Life Sciences Expand Partnership to Develop AI-Powered Cancer Diagnostics
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has announced a strategic partnership agreement...
Deals
Bayer Extends Collaboration with Broad Institute to 2028 for Oncology Drug Targets and Therapies
Germany’s Bayer (NYSE: ETR) has announced the extension of its 2013 collaboration agreement with the...
AbbVie Secures Option Agreement with Aldeyra Therapeutics for RASP Modulator Reproxalap
AbbVie (NYSE: ABBV) has entered into an option agreement with Aldeyra Therapeutics (NASDAQ: ALDX), a...
Sanofi Regains Exclusive Rights to Rezurock in China, Terminating Agreement with BioNova and BK Pharmaceuticals
BioNova Pharmaceuticals, a Shanghai-based oncology-focused biopharmaceutical company founded in 2018, and Sanofi (NASDAQ: SNY), a...
AstraZeneca Partners with Cellectis for Next-Generation Cell and Gene Therapies
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced a strategic partnership with Cellectis (EPA:...
We-Linking Secures Angel Financing for Implantable Brain Computer Interface Development
Shenzhen-based company We-Linking, a specialist in implantable brain computer interfaces (BCI), has reportedly raised tens...
3SBio Inc. and CStone Pharmaceuticals Enter Strategic Partnership for Nofazinlimab
China-based 3SBio Inc., (HKG: 1530) has announced a strategic partnership and exclusive licensing agreement with...
Resolian Expands Global Reach with Acquisition of China-Based Denali Medpharma
US-based bioanalytical contract research organization (CRO) Resolian has announced the acquisition of China-based CRO Denali...
Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round
Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million)...
ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development
ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100...
AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib
China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma...
BioLineRx Licenses Multiple Myeloma Drug Motixafortide to Guangzhou Gloria Biosciences
Israel’s BioLineRx has entered into a licensing agreement with Guangzhou Gloria Biosciences Co., Ltd., based...
Triastek Partners with BASF to Advance 3D Printing Materials for Pharmaceuticals
China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with...
Novo Nordisk Acquires Global License for Vect-Horus Molecular Cargo Delivery Platform
Novo Nordisk (NYSE: NVO), a leading pharmaceutical company based in Denmark, has obtained an exclusive...
Merck KGaA and Jiangsu Hengrui Ink Strategic Collaboration Deal for Next-Gen PARP1 Inhibitor
Germany-based Merck KGaA (NYSE: MRK) has announced the signing of a strategic collaboration deal with...
Danyang Huichuang Secures Over USD 13.7 Million in Series B Funding for fNIRS Development
Danyang Huichuang Medical Equipment Co., Ltd, a China-based specialist in functional near-infrared spectroscopy (fNIRS), has...
BMS and Karyopharm Partner to Evaluate Mezigdomide and Xpovio in Relapsed/Refractory Multiple Myeloma
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into a collaboration and supply agreement with...
Shanghai Henlius Biotech and Intas Pharmaceuticals Ink New Licensing Deal for PD-1 mAb
China’s Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new licensing agreement with India-based...
Strategic Alliance Formed by uBriGene, Fraserna, and Virogin for Cell and Gene Therapy Services
In a significant move to bolster the cell and gene therapy (CGT) sector, China-based biotechnology...
Sinotau Pharmaceutical Group Secures Rights to Blue Earth Diagnostics’ Flotufolastat in China
Sinotau Pharmaceutical Group, a Beijing-based nuclear medicine enterprise, has entered into a licensing agreement with...